Home › Leukemia › Illinois › Chicago
Pag-aaral pangklinika para sa Leukemia sa Chicago, IL
16 pag-aaral para sa Leukemia ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Chicago (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Nagre-recruitPhase 1/2
- The University of Chicago Medical Center, Chicago
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Nagre-recruitPhase 3
- Research Site, Chicago
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
Nagre-recruitPhase 1/2
- University of Chicago, Chicago
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Nagre-recruitPhase 1
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Nagre-recruitPhase 1/2
- Research Site, Chicago
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Nagre-recruitPhase 2
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Mosaic Trial for Stem Cell Transplant Recipients
Nagre-recruit
- Northwestern University Feinberg School of Medicine, Chicago
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
Nagre-recruitPhase 2
- University of Chicago Medical Center, Chicago
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Nagre-recruitObservasyonal na pag-aaral
- Lurie Children's Hospital-Chicago, Chicago
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Nagre-recruitPhase 1/2
- University of Illinois at Chicago Cancer Center, Chicago
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Nagre-recruitPhase 1
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL
Nagre-recruitPhase 1/2
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
Spiritual Care Intervention in Adult Patients Diagnosed With Acute Leukemia
Nagre-recruit
- UChicago Medicine Comprehensive Cancer Center, Chicago
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
Nagre-recruit
- University of Chicago Comprehensive Cancer Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Nagre-recruitObservasyonal na pag-aaral
- Massive Bio SYNERGY-AI site, Chicago
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Nagre-recruitPhase 1
- Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion, Chicago
Pag-aaral para sa Leukemia sa ibang lungsod
- Houston, TX28 pag-aaral
- Boston, MA25 pag-aaral
- New York City, NY19 pag-aaral
- Los Angeles, CA16 pag-aaral
- Durham, NC13 pag-aaral
- Philadelphia, PA12 pag-aaral
- Nashville, TN12 pag-aaral
- Columbus, OH12 pag-aaral
- Baldwin Park, CA12 pag-aaral
- Milwaukee, WI11 pag-aaral
- Seattle, WA11 pag-aaral
- Aurora, CO10 pag-aaral
Iba pang pag-aaral sa Chicago
- Non-Small Cell Lung Cancer62 pag-aaral
- Kanser sa Suso58 pag-aaral
- Kanser (lahat ng uri)53 pag-aaral
- Metastatic Cancer45 pag-aaral
- Kanser sa Prostate45 pag-aaral
- Obesity42 pag-aaral
- Kanser sa Baga41 pag-aaral
- Kanser sa Ovary36 pag-aaral
- Stroke35 pag-aaral
- Pagkabigo ng Puso32 pag-aaral
- Colorectal Cancer32 pag-aaral
- Overweight28 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.